When contextualised against the 2025 ELSO quarterly report (n = 6 142 VV-ECMO runs, 38% COVID-19), our cohort exhibited comparable 28-day survival (39% vs. 41%) yet a shorter median IL-6 half-life (31 h vs. 46 h), possibly reflecting the routine use of high-cut-off filters in our centres. This evidence concerns the gene IL6 and COVID-19.